Architect System

Device Abbott Laboratories
Total Payments
$4.5M
Transactions
34
Doctors
0
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2020 $4.5M 34 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $4.5M 34 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Evaluation of Cardiovascular Biomarkers in the Randomized Evaluation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) TIMI-55 Abbott Laboratories $3.6M 0
Atherosclerosis Risk in Communities (ARIC) Abbott Laboratories $422,796 0
Evaluation of Cardiovascular Biomarkers in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (Fourier TIMI 59) Abbott Laboratories $132,200 0
WYOMING Clinical Specimen Collection Protocol for Evaluation of Abbott Laboratories in Vitro Diagnostic Assays Abbott Laboratories $95,278 0
CMR Impact Abbott Ancillary Study Abbott Laboratories $84,084 0
Dried Blood Spots Study Abbott Laboratories $71,749 0
Human Specimen Collection Abbott Laboratories $40,000 0
Surveillance of Covid-19 exposures during early pregnancy in Rhode Island Abbott Laboratories $31,391 0
MultIethNic Study of BrEast ARterial Calcium Gradation and CardioVAscular Disease Biomarkers Sub-study Abbott Laboratories $30,000 0
Abbott Brainstorm Medical Phase I data analysis protocol Abbott Laboratories $25,000 0

Top Doctors Receiving Payments for Architect System

Doctor Specialty Location Total Records
Unknown Boston, MA $4.5M 34

About Architect System

Architect System is a device associated with $4.5M in payments to 0 healthcare providers, recorded across 34 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.

Payment data is available from 2020 to 2020. In 2020, $4.5M was paid across 34 transactions to 0 doctors.

The most common payment nature for Architect System is "Unspecified" ($4.5M, 100.0% of total).

Architect System is associated with 10 research studies, including "Evaluation of Cardiovascular Biomarkers in the Randomized Evaluation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) TIMI-55" ($3.6M).